The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts).
Sagar D Sardesai
No relevant relationships to disclose
Wei Tan
No relevant relationships to disclose
Laurie Ann Ford
No relevant relationships to disclose
George Deeb
No relevant relationships to disclose
Anne Marie W. Block
No relevant relationships to disclose
Sheila N.J. Sait
No relevant relationships to disclose
Philip L. McCarthy
No relevant relationships to disclose
Carlos E Vigil
No relevant relationships to disclose
Elizabeth A. Griffiths
No relevant relationships to disclose
James E Thompson
No relevant relationships to disclose
Eunice S. Wang
No relevant relationships to disclose
Paul K Wallace
No relevant relationships to disclose
Meir Wetzler
No relevant relationships to disclose